Could you provide a breakdown of the latest FDA-approved insomnia medications, specifically focusing on dual orexin receptor antagonists and their long-term dependency risks?
Download run
Fan-out diagram
The searches the AI actually ran for this prompt.
SEED QUERY
Could you provide a breakdown of the latest FDA-approved insomnia medications, specifically focusing on dual orexin receptor antagonists and their long-term dependency risks?
2 real searches · 1 real-search pass
FDA approved insomnia medications dual orexin receptor antagonists prescribing information long term dependence withdrawal daridorexant lemborexant suvorexant 2026Google ↗
OBSERVEDOther / navigational
FDA insomnia treatment medications approved 2025 2026 dual orexin receptor antagonists latest approvalGoogle ↗
OBSERVEDShort fact
Badge and edge weight = share of passes that produced the query. Hover a query for its intent and routing format.
Query classes
Google's semantic query class for every sub-query: what kind of answer each search is after, simulated vs real.
ChatGPT real searches (2)
Classes come from the query-classifier (a local Laya model). 2 of 2 calls are low-confidence (under 50%) — hover a query in the table to see its confidence.
Searches and sources
ChatGPT2 real searches · gpt-6
FDA approved insomnia medications dual orexin receptor antagonists prescribing information long term dependence withdrawal daridorexant lemborexant suvorexant 2026 Google ↗
FDA insomnia treatment medications approved 2025 2026 dual orexin receptor antagonists latest approval Google ↗
- Orexin Receptor Therapies for Insomnia and Narcolepsy Type 1 | National Institute of Neurological Disorders and Stroke · ninds.nih.gov
- These highlights do not include all the information needed to use QUVIVIQ safely and effectively. See full prescribing information for QUVIVIQ. QUVIVIQ (daridorexant) tablets, for oral use, CIV Initial U.S. Approval: 2022 · dailymed.nlm.nih.gov
- Drug Trials Snapshots: QUVIVIQ · fda.gov
- Current and novel dual orexin receptor antagonists for the treatment of insomnia: the emergence of vornorexant | International Journal of Neuropsychopharmacology · academic.oup.com
- label · accessdata.fda.gov
- label · accessdata.fda.gov
- Schedules of Controlled Substances: Rescheduling of Suvorexant, Lemborexant, and Daridorexant From Schedule IV Into Schedule V · thefederalregister.org
- Chronic Insomnia - StatPearls · ncbi.nlm.nih.gov
- These highlights do not include all the information needed to use RAMELTEON TABLETS safely and effectively. See full prescribing information for RAMELTEON TABLETS. RAMELTEON tablets, for oral use Initial U.S. Approval: 2005 · dailymed.nlm.nih.gov
- 2025 VA/DoD Chronic Insomnia & Obstructive Sleep Apnea Clinical Guideline - Guideline Summary · guidelinecentral.com
Queries
2 queries · click a column to sort
| Query / type | Search | Intent | Query class | Routing format | Cluster | Freq ↓ | Weight |
|---|---|---|---|---|---|---|---|
FDA approved insomnia medications dual orexin receptor antagonists prescribing information long term dependence withdrawal daridorexant lemborexant suvorexant 2026 OBSERVED | Google ↗ AI Mode ↗ | — | Other / navigational | — | — | 1x of 1 | |
FDA insomnia treatment medications approved 2025 2026 dual orexin receptor antagonists latest approval OBSERVED | Google ↗ AI Mode ↗ | — | Short fact | — | — | 1x of 1 |